Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome
In addition to the glycemic control, these agents have shown considerable cardiovascular advantages that have been confirmed by large-scale cardiovascular outcome trials (CVOTs) that have shown reductions in major adverse cardiovascular events (MACE), including myocardial infarction (MI), stroke, and cardiovascular death [6,7]
Gaur P, Sepesi B, Hofstetter WL , Correa AM, Bhutani MS, Ajani JA, Erasmus J, Komaki R, Lee JHL, Maru D, Mehran R, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Peters JH, Watson TJ, Swisher SG
Int J Basic Appl Med Sci
Lerno LA, Panprivech S, Ponangi R, Brenneman CA, Block DE, Oberholster A
US$ 22.97
US$ 28.46
US$ 29.13
US$ 27.62
